Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium

Journal of Medical Economics

Volumn 16, Issue 3, 2013, Pages 407-414

  Wouters, Hanne ^a   Thijs, Vincent ^b,c,d   Annemans, Lieven ^e  

^a Boehringer Ingelheim   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e GHENT UNIVERSITY   (Belgium)

Author keywords

Atrial fibrillation; Belgium; Cost effectiveness; Dabigatran etexilate; Stroke; Warfarin

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIVITAMIN K; DABIGATRAN ETEXILATE; PHENPROCOUMON; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BELGIUM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; EMBOLISM PREVENTION; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; META ANALYSIS (TOPIC); MODEL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; ATRIAL FIBRILLATION; BELGIUM; BENZIMIDAZOLES; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; EMBOLISM; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PYRIDINES; QUALITY-ADJUSTED LIFE YEARS; STROKE;

EID: 84873902013     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.766200     Document Type: Article

References (40)

1. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429
2. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53
3. Claes N, Van Laethem C, Goethals M, et al. Prevalence of atrial fibrillation in adults participating in a large-scale voluntary screening programme in Belgium. Acta Cardiol 2012;67:273-8
4. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the ATRIA Study. JAMA 2001;85:2370-5
5. Rietbrock S, Heeley E, Plumb J, et al. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the Congestive heart failure, hypertension, age 475, diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J 2008;156:57-64
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation Framingham Study. Stroke 1991;22:983-8
7. Frost L, Engholm G, Johnsen S, et al. Incident thromboembolism in the aorta and the renal, mesenteric, pelvic, extremity arteries after discharge from the hospital with a diagnosis of atrial fibrillation. Arch Intern Med 2001;161:272-6
8. Thijs V, Dewilde S, Putman L, et al. Cost of hospitalization for cerebrovascular disorders in Belgium. Acta Neurol Belg 2011;111:104-10
9. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation 2006;114:e257-354
10. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:546-92
11. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67
12. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anti-coagulation control: a systematic review and metaregression. Chest 2006;129:1155-66
13. Dolan G, Smith LA, Collins S, et al. Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature. Curr Med Res Opin 2008;24:1459-72
14. Claes N. Quality of oral anticoagulation in patients with atrial fibrillation: a cross-sectional study in general practice. Eur J Gen Pract 2006;12:163-8
15. Nieuwlaat R, Capucci A, Camm AJ, et al; on behalf of the Euro Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC Member Countries. The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422-34
16. 2 score in primary care patients with hypertension: the Belgica-Stroke Study, 2010 (abstract and poster)
17. De Breucker S, Herzog G, Pepersack T. Could geriatric characteristics explain the under-prescription of anticoagulation therapy for older patients admitted with Atrial Fibrillation? A retrospective observational study. Drugs Aging 2010;27:1-7
18. Connolly SJ, Ezekowitz MD, Yusuf S, et al; the RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in patients with Atrial Fibrillation. N Engl J Med 2009;361:1139-51
19. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Randomized evaluation of long-term anticoagulation therapy investigators. Newly identified events in the RELY Trial. N Engl J Med 2010;363:1875-6
20. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011;105:909-19
21. Pink J, Lane S, Pirmohamed M, et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 2011;343:d6333
22. Kansal AR, Sorensen SV, Gani R, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 2012;98:573-8
23. Langkilde LK, Asmussen MB, Overgaard M. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark. J Med Econ 2012;15:1-9
24. Davidson T, Husberg M, Janzon M, et al. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. Eur Heart J 2013; 34(3):177-83
25. Sorensen SV, Dewilde S, Singer DE, et al. Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. Am Heart J 2009;157:1064-73
26. Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: network meta-analyses and indirect comparisons versus dabiga-tran etexilate. Thromb Haemost 2010;104:1106-15
27. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26
28. Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004;164:880-4
29. Bevolking-Sterftetafels, België1997-2009, Statbel. Brussels: Algemene Directie Statistiek en Economische Informatie, 2011. www.statbel.fgov.be. Accessed June 8, 2011.
30. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156:1829-36
31. Sullivan PW, Arant TW, Ellis SL, et al. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 2006;24:1021-33
32. Pradaxa. Summary of Product Characteristics. Community register of medicinal products for human use. Brussels: European Commission, 2012. http://ec.europa.eu/health/documents/community-register/html/h442.htm.http://ec. europa.eu/health/documents/community-register/html/h442.htm Accessed July 10, 2012
33. Yousef ZR, Tandy SC, Tudor V, et al. Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital. Heart 2004;90:1259-62
34. Walker AM, Bennett D. Epidemiology and outcomes in patients with atrial fibrillation in the United States. Heart Rhythm 2008;5:1365-72
35. Gailly J, Gerkens S, Van Den Bruel A, et al. Use of point-of care devices in patients with oral anticoagulation: a health technology assessment. Health Technology Assessment (HTA). Brussels: Belgian Health Care Knowledge Centre (KCE), 2009. KCE Reports vol 117C
36. Databank Farmaceutische Specialiteiten. Rijksinstituut voor Ziekte-en Invaliditeitsverzekering (RIZIV). Brussels: Rijksinstituut voor Ziekte-en Invaliditeitsverzekering, 2012. http://www.riziv.fgov.be/drug/nl/drugs/index. htm. Accessed April 20, 2012
37. NomenSoft databank. Rijksinstituut voor Ziekte-en Invaliditeitsverzekering (RIZIV). Brussels: Rijksinstituut voor Ziekte-en Invaliditeitsverzekering, 2012. https://www.riziv.fgov.be/webprd/appl/pnomen/ Search.aspx?lg= N.Accessed April 20, 2012
38. Cleemput I, Van Wilder P, Vrijens F, et al. Guidelines for pharmacoeconomic evaluations in Belgium. Health Technology Assessment (HTA). Brussels: Health Care Knowledge Centre (KCE); 2008. KCE Reports 78C
39. Consumptieprijsindex vanaf 1920 en gezondheidsindex vanaf 1994. Brussels: FOD Economie, K.M.O, Middenstand en Energie, 2012. http://economie.fgov.be/nl/ modules/publications/statistiques/economie/prijzen-consumptieprijsindex-vanaf- 1920-en- gezondheidsindex-vanaf-1994.jsp. Accessed April 20, 2012.
40. Robinson A, Thomson R, Parkin D, et al. How patients with atrial fibrillation value different health outcomes: a standard gamble study. J Health Serv Res Policy 2001;6:92-8.